CRBU
Caribou Biosciences, Inc.
Biotechnology · Healthcare · United States
0.42
close · 2026-10-30
value
4
cheaper than peers4
quality
9
stronger fundamentals9
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.46× | 94 |
| price to sales | 4.52× | 71 |
| cash flow yield, 3 years ago | -216.0% | 6 |
| earnings yield, 2 years ago | -326.1% | 5 |
| earnings yield, 3 years ago | -387.5% | 5 |
| earnings yield, 1 year ago | -389.9% | 4 |
| earnings yield, latest year | -375.7% | 4 |
| cash flow yield, latest year | -247.6% | 4 |
| cash flow yield, 1 year ago | -318.9% | 3 |
| cash flow yield, 2 years ago | -231.2% | 3 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 27.2% | 40 |
| return on equity | -78.3% | 31 |
| revenue growth | -43.8% | 21 |
| operating margin | -1690.4% | 14 |
4 of 4 measures available
Facts
| market cap | $45M |
| free cash flow | -$59.6M |
| employees | 97 |
| first trade | 2021-07-23 |
| next earnings | not reported |
| fundamentals updated | 2026-08-17 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.59 | -1.65 | -1.38 | -1.64 |
| free cash flow | -$112.4M | -$144.7M | -$104.9M | -$98.0M |
| net income | -$148.1M | -$149.1M | -$102.1M | -$99.4M |
| revenue | $11.2M | $10.0M | $34.5M | $13.9M |
| unusual items | -$21.3M | $0 | -$6,000 | -$133,000 |